Angina Pectoris - Pipeline Insight, 2024

This “Angina Pectoris- Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Angina Pectoris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Angina Pectoris Understanding

Angina Pectoris: Overview

Angina is chest discomfort or pain caused by reduced blood flow to the heart muscle. Treatment primarily involves relieving symptoms by resting and using angina medications, as well as lifestyle changes to improve overall heart health. Angina, which is also known as angina pectoris, occurs when the flow of blood through the coronary arteries to the heart muscle is insufficient to meet the heart’s oxygen demands, such as during physical activity.Coronary heart disease is the most common cause of reduced blood flow to the heart in people with angina. Coronary heart disease is the build-up of fatty deposits on the inside of the coronary arteries causing them to become narrow and restricting the amount of blood flowing to the heart muscle. Angina differs from a heart attack because the reduction in blood flow to the heart muscle is only temporary and does not result in damage to the heart muscle. During a heart attack, the interrupted blood flow can result in the heart muscle being damaged or destroyed. People with angina, however, are at higher risk of having a heart attack. There are two main types of angina: Stable angina: pain lasting 5-15 minutes that is relieved by angina medication. It usually has a trigger, such as physical exercise or exertion, anxiety or emotional stress, cold temperatures, or heavy meals. Unstable angina: pain lasting longer than 15 minutes that may not be fully relieved by angina medication. It may indicate that you are having a heart attack. Unstable angina often occurs without a specific trigger. Angina symptoms are not always present because during times of low oxygen demand, e.g. when at rest, the heart muscle can function on the reduced amount of blood flow without triggering symptoms. However, when heart doesn’t get enough oxygen (e.g. during exercise) angina symptoms are triggered. Tests are available to help confirm a diagnosis of angina. These include: electrocardiogram (ECG), exercise stress test, echocardiogram, chest x-ray, coronary angiography and computerised tomography (CT) scan and magnetic resonance imaging (MRI) which can show if the heart is enlarged or the coronary arteries are narrowed. To reduce the frequency and severity of your angina symptoms and improve general heart health over time, a range of options may be recommended, from self-management and lifestyle changes to medications, and in some cases surgery.

Angina Pectoris- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Angina Pectoris pipeline landscape is provided which includes the disease overview and Angina Pectoris treatment guidelines. The assessment part of the report embraces, in depth Angina Pectoris commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Angina Pectoris collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Angina Pectoris R&D. The therapies under development are focused on novel approaches to treat/improve Angina Pectoris.

Angina Pectoris Emerging Drugs Chapters

This segment of the Angina Pectoris report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Angina Pectoris Emerging Drugs

CLBS14: Caladrius Biosciences CLBS14 belongs to the CD34+ cell therapy program for NORDA (No-option refractory disabling angina, describes patients who have severe and disabling angina, which persists despite revascularization (e.g. bypass surgery or stenting) and optimal medical therapy) . Based on the clinical evidence from the completed studies, a single administration of OLOGO™ reduces mortality, improves angina, and increases exercise capacity in patients with otherwise untreatable angina. This product has received a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. Notably, the RMAT designation affords the product a more rapid 6-month review time for a biologics license application (BLA), oncesubmitted.

IMB-101: Imbria Pharmaceuticals IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (p FOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency. IMB-101 is designed to enhance cellular energy metabolism by increasing the amount of energy produced per molecule of oxygenconsumed.

XC001: Xylocor Therapeutics XC001 is an investigational gene therapy for the treatment of patients with refractory angina with no treatment options. Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid deterioration of their health status and results in a poor quality of life because of the associated chest pain caused by the ischemia when even moderate physical exertion occurs. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. This treatment strategy is based on both pre-clinical and clinical evidence and should enable the patients to become less limited in their daily activities because of debilitating chest pain. An Investigational New Drug (IND) application for XC001 is open with the FDA. XyloCor commenced this Phase 1/2 trial in refractory angina in early 2020.

CKD385: Chong Kun Dang CKD385,belongs to the class of Ischaemic heart disorder therapies. Mechanisms of action for these interventions include heart rate modulation, vascular smooth muscle relaxation, metabolic manipulation, revascularization, and others. A number of these interventions have overlapping mechanisms that target angina.The drug is currently being investigated in Phase I stage of development for the treatment of AnginaPectoris.

Angina Pectoris: Therapeutic Assessment

This segment of the report provides insights about the different Angina Pectoris drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Angina Pectoris

There are approx. 10+ key companies which are developing the therapies for Angina Pectoris. The companies which have their Angina Pectoris drug candidates in the most advanced stage, i.e. phase III include, Caladrius Biosciences

Phases

This report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Angina Pectoris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Angina Pectoris: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Angina Pectoris therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Angina Pectoris drugs.

Angina Pectoris Report Insights

• Angina Pectoris Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Angina Pectoris Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Angina Pectoris drugs?
• How many Angina Pectoris drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Angina Pectoris?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Angina Pectoris therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Angina Pectoris and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Abbott Laboratories
• Astra Zeneca
• Bayer AG
• Bristol-Myers Squibb Company
• F. Hoffmann-La Roche Ltd.
• Allergan
• GlaxoSmithKline
• Novartis AG
• Pfizer
• Sanofi
• Xylocor Therapeutics
• Imbria Pharmaceuticals
• Chong Kun Dang
• Caladrius Biosciences

Key Products

• XC-001
• IMB-101
• CKD385
• CLBS14

This product will be delivered within 1-3 business days.